Amarin Submits Supplemental NDA to FDA for BASF as Additional Vascepa Active Pharmaceutical Ingredient Supplier

Amarin Submits Supplemental NDA to FDA for BASF as Additional Vascepa Active Pharmaceutical Ingredient Supplier

By: Latest Articles from Benzinga.com

Posted on January 02, 2013 at 07:43 AM EST

Amarin Corporation (NASDAQ: AMRN ) announced today the late December 2012 submission of a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for BASF (OTC: BASFY ) as an additional Vascepa® (icosapent ethyl) active pharmaceutical ingredient (API) supplier. "This sNDA submission for

Related Stocks:

Amarin Corp Plc BASF SE American Depositary Shares GBL INV HSE NewStar Financial, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates